

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

**SUPPLEMENTAL ANNOUNCEMENT TO
THE INSIDE INFORMATION AND OVERSEAS REGULATORY
ANNOUNCEMENT: UPDATE ON RESTATEMENT OF
FINANCIAL STATEMENTS OF LEGEND BIOTECH**

This announcement is made by the board of directors (the “**Board**”) of the Genscript Biotech Corporation (the “**Company**”) pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the inside information and overseas regulatory announcement of the Company dated 19 February 2023 in relation to the update on restatement of financial statements of Legend Biotech (the “**Previous Announcement**”). Unless otherwise defined terms used herein shall bear the same meanings as defined in the Previous Announcement.

As disclosed in the Previous Announcement, Legend Biotech filed with the SEC in relation to the Affected Financials on 17 February 2023, among others, the Amendment No. 1 on Form 20-F/A to the Annual Report on Form 20-F for the fiscal year ended 31 December 2021 to, among others, amend and restate the audited financial statements of Legend Biotech as at 31 December 2021 and 31 December 2020, and for the years ended 31 December 2021, 31 December 2020 and 31 December 2019 (the “**Form 20-F/A**”).

For information purpose, the Company hereby provides the Chinese translation of selected disclosures of the Form 20-F/A relating to, among others, the amended items as disclosed in the Form 20-F/A, including without limitation, the Legend Restatement, Affected Financials, risk factors, and controls and procedures relating to disclosures and financial reporting.

The Form 20-F/A was originally prepared in English and has been attached to the Previous Announcement in full.

If there is any inconsistency or ambiguity between the English version of the Form 20-F/A and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
GenScript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 1 March 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

** For identification purposes only*